Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8639958 | 0.88 | — | — | |
| SCHEMBL5020014 | 0.79 | — | — | |
| SCHEMBL1714494 | 0.74 | SORT1 (0.37) | DAOGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL11023566 | 0.74 | APP (0.32) | — | |
| SCHEMBL9498695 | 0.72 | CRBN (0.32) | ALDH1A1DDB1CRBN | |
| SCHEMBL9674369 | 0.72 | ALDH1A1 (0.35) | ALDH1A1HTR1DKDM4EHSD17B10 | |
| Hydrochloric Acid SCHEMBL9671810 | 0.71 | ALDH1A1 (0.34) | ALDH1A1HTR1DKDM4EHSD17B10 | |
| Hydrochloric Acid SCHEMBL9673463 | 0.71 | KDM4E (0.37) | ALDH1A1KDM4ELMNAGAATSHR | |
| SCHEMBL1755701 | 0.70 | — | — | |
| SCHEMBL11416505 | 0.68 | SCD (0.36) | ALDH1A1KDM4ELMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111592495-A | Preparation method of 2-n-butyl-4-chloro-5-formylimidazole | 上海启讯医药科技有限公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-103214420-B | Method for preparing 2-butyl-4-chloro-5-formylimidazole | TAIZHOU VOCATIONAL & TECHNICAL COLLEGE | 2015-04-08 | — | — | CN | disclosed |
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| EP-2094699-B1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI AVENTIS (FR) | 2011-07-20 | — | — | EP | disclosed |
| EP-2094699-B1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI AVENTIS (FR) | 2011-07-20 | — | — | EP | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-5536841-A | Process for the preparation of 2-substituted 5-chloroimidazole-4-carbaldehydes | LONZA LTD. (CH) | 1996-07-16 | — | — | US | disclosed |
| US-5508425-A | REACTION OF GLYCINE ESTER HYDROHALIDE WITH AMIDIC ACID ESTER TO FORM 3,5-DIHYDROIMIDAZOLE-4-ONE, CHLORINATION | LONZA LTD. (CH) | 1996-04-16 | — | — | US | disclosed |
| US-5486617-A | Process for the preparation of 2-substituted 5-chloroimidazole-4-carbaldehydes | LONZA LTD. (CH) | 1996-01-23 | — | — | US | disclosed |
| US-5484939-A | 2-substituted 5-chlorimidazoles | LONZA LTD. (CH) | 1996-01-16 | — | — | US | disclosed |
| US-5442075-A | Reacting glycine ester hydrohalide with imidic acid ester in presence of base and solvent, reacting product with phosgene or phosphoroxy chloride and dimethylformamide | LONZA LTD. (CH) | 1995-08-15 | — | — | US | disclosed |
| EP-0653422-A1 | Process for the preparation of 2-substituted 5-chlorimidazole-4-carbaldehydes | LONZA AG (CH) | 1995-05-17 | — | — | EP | disclosed |
| EP-0614892-A1 | Process of preparation of optionally 2-substituted 5-chlorimidazol-4-carbaldehydes | LONZA AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| EP-0614891-A2 | Optionally 2-substituted 5-chloroimidazoles | LONZA AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| EP-0614889-A1 | Process of preparation of optionally 2-substituted 5-chlorimidazol-4-carbaldehydes | LONZA AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| EP-0614890-A2 | Optionally 2-substituted 5-chloroimidazoles | LONZA AG (CH) | 1994-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | CDC7, CDK7, CDK17 | ALDH1A1 4307/4885HTR1D 4745/4885DDB1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.